Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13615982 | 0.91 | BRD4 (0.33) | BRD4 | |
| SCHEMBL8269502 | 0.87 | BRD4 (0.35) | BRD4HCN4 | |
| SCHEMBL14845339 | 0.87 | BRD4 (0.38) | BRD4HCN4 | |
| SCHEMBL8277866 | 0.84 | BRD4 (0.37) | BRD4HCN4 | |
| SCHEMBL15044209 | 0.82 | BRD4 (0.32) | BRD4 | |
| SCHEMBL7950678 | 0.79 | BRD4 (0.33) | BRD4 | |
| SCHEMBL16140055 | 0.77 | BRD4 (0.57) | BRD4 | |
| SCHEMBL16140066 | 0.71 | MEN1 (0.42) | BRD4HCN4 | |
| SCHEMBL6848710 | 0.70 | HCN4 (0.57) | BRD4HCN4 | |
| SCHEMBL15858417 | 0.70 | BRD4 (0.63) | BRD4HCN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927708-B2 | Process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one compounds, and application in the synthesis of ivabradine | LES LABORATOIRES SERVIER (FR) | 2015-01-06 | — | — | US | disclosed |
| US-20140296512-A1 | PROCESS FOR THE SYNTHESIS OF 7,8-DIMETHOXY-1,3-DIHYDRO-2H-3-BENZAZEPIN-2-ONE COMPOUNDS, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE | LES LABORATOIRES SERVIER (FR) | 2014-10-02 | — | — | US | disclosed |
| US-8835627-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2014-09-16 | — | — | US | disclosed |
| US-20130261298-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2013-10-03 | — | — | US | disclosed |
| US-8476426-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2013-07-02 | — | — | US | disclosed |
| EP-2202225-B1 | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | SERVIER LAB (FR) | 2012-10-24 | — | — | EP | disclosed |
| US-8278440-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-10-02 | — | — | US | disclosed |
| US-8278440-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-10-02 | — | — | US | disclosed |
| EP-2364972-B1 | New method for synthesising ivabradine and its addition salts | SERVIER LAB (FR) | 2012-09-19 | — | — | EP | disclosed |
| US-20120208996-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20100249398-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249397-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-09-30 | — | — | US | disclosed |
| WO-2010089475-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE AND THE PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | LES LABORATOIRES SERVIER (FR) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010072930-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE | LES LABORATOIRES SERVIER (FR) | 2010-07-01 | — | — | WO | disclosed |
| EP-2202225-A1 | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | Les Laboratoires Servier (FR) | 2010-06-30 | — | — | EP | disclosed |
| US-20100160628-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-06-24 | — | — | US | disclosed |
| US-20070135411-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2007-06-14 | — | — | US | disclosed |
| EP-1589005-B1 | Process for the synthesis of Ivabradine and its pharmaceutically acceptable acid addition salts | SERVIER LAB (FR) | 2007-03-28 | — | — | EP | disclosed |
| US-7176197-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2007-02-13 | — | — | US | disclosed |
| WO-2005110993-A1 | NOVEL METHOD OF SYNTHESISING IVABRADINE AND THE SALTS THEREOF FOR ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208996-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | BRD4 4035/4885HCN4 37/4885 |
| US-20140296512-A1 | PROCESS FOR THE SYNTHESIS OF 7,8-DIMETHOXY-1,3-DIHYDRO-2H-3-BENZAZEPIN-2-ONE COMPOUNDS, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE | KCNB1, KCNB2, KCNMB1 | BRD4 1157/4885HCN4 95/4885 |
| US-20070135411-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | SCN5A, NISCH, CYP4F2 | BRD4 4110/4885HCN4 9/4885 |
| US-20100249398-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | BRD4 4035/4885HCN4 37/4885 |
| US-20130261298-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | BRD4 4035/4885HCN4 37/4885 |
| US-20100160628-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | BRD4 4035/4885HCN4 37/4885 |
| US-20100249397-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | BRD4 4035/4885HCN4 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.